Renal
ischemia/reperfusion (I/R) injury is strongly related to morbidity and mortality. Oxidative stress,
inflammation, and apoptosis play key roles in renal dysfunction following renal I/R.
Aripiprazole is an atypical
antipsychotic which used for the treatment of
schizophrenia and
bipolar disorder. Recent studies have reported
aripiprazole as displaying certain anti-inflammatory effects. Regarding the underlying mechanisms of renal
ischemia-reperfusion, therefore, nephroprotective effects might be predicted to be seen with
aripiprazole. I/R injury was induced by bilateral clamping of the renal pedicles (45min) followed by reperfusion (24h). The mechanism of
aripiprazole-mediated nephroprotection was explored by a combined use of
aripiprazole and
L-NAME (non-selective
nitric oxide synthase inhibitor). Animals were given
aripiprazole (2.5, 5, 10 and 20mg/kg) intraperitoneally, 30min before
ischemia.
L-NAME was administered before the
aripiprazole injection. Serum
creatinine and blood
urea nitrogen were assessed after 24h of reperfusion. Serum levels of
malondialdehyde (MDA), TNF-α and IL-1β were measured for rats treated with
aripiprazole. The extent of
necrosis was measured by the stereology method.
Ischemia/reperfusion caused significant renal dysfunction and marked renal injury.
Aripiprazole reduced
creatinine and blood
urea nitrogen. Serum levels of MDA, IL-1β and TNF-α were significantly lower in the
aripiprazole group.
Aripiprazole treatment also decreased the volume of kidney
necrosis. The administration of
L-NAME reversed the renoprotective effect of
aripiprazole on BUN and
creatinine, but enhanced the anti-necrotic effect of
aripiprazole. The results show that a single dose of
aripiprazole significantly improved renal function following
ischemia/reperfusion injury - probably through the involvement of
nitric oxide.